Search Results for: COLORECTAL CANCER MARKET Targeted Immune
Articles
COLORECTAL CANCER MARKET - Targeted & Immune System-Based Therapeutics Emerge as Prominent Treatment Modalities November 18, 2015
Barbara Gilmore, Frost & Sullivan Analyst, reports that a vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and significant commercial potential are attracting drug developers to the market.
DRUG DEVELOPMENT - Using a Novel Deep Cyclic Inhibition Mechanism to Treat Broad Range of RAS-Mutant Cancers January 26, 2024
Ben Zeskind, PhD, addresses the question: rather than targeting individual RAS mutations and treating chronically, is it possible to achieve broad therapeutic activity in a way that focuses on malignant cells while minimizing damage to healthy cells?
Global DNA Sequencing: Research, Applied & Clinical Markets June 24, 2019
The global sequencing market should grow from $10.7 billion in 2018 to $24.4 billion by 2023, with a compound annual growth rate (CAGR) of 18.0% for the period of 2018-2023.
EXECUTIVE INTERVIEW - BriaCell Therapeutics: Recognizing the Power of Targeted Immunotherapies October 1, 2018
Dr. William “Bill” Williams, MD, President and CEO of BriaCell Therapeutics, discusses the value of targeted immunotherapies in the biopharmaceutical industry.
EXECUTIVE INTERVIEW - Viral Gene: Protein-Targeting Cancer Vaccine Could Boost Survival Rates January 13, 2017
Harry A. Arena, MBA, President & CEO of TDT, Chris Kim, President & General Counsel, Viral Gene, Inc., and Dr. Scott Waldman, Professor & Chair of Sidney Kimmel Medical College’s Department of Pharmacology & Experimental Therapeutics at Thomas Jefferson University, discuss the unique characteristics of the vaccine, the patients who will benefit the most, and how a research team captured the attention of investors.
Viral Gene Announces Breakthrough in Colon Cancer October 28, 2016
Philadelphia, PA – October 28, 2016 - Colorectal cancer kills more than 49,000 Americans each year and is the second-leading...GLOBAL DELIVERY MARKET - Advanced Drug Delivery Systems: mAb, RNAi, & Breaking the Blood-Brain Barrier November 19, 2014
Kevin James, Shalini Dewan, MS, Kim Lawson, and Usha Nagavarapu believe advances in understanding human biology and diseases are opening new and exciting possibilities in the biotechnology industry. R&D spending, along with increasing competition, patent expiries, and new and emerging technologies will continue to shape growth in this market for the foreseeable future.
US Nanotechnology Drug Delivery Market Forecast to Grow Significantly Through 2016 April 8, 2013
Research activities in healthcare have changed significantly in recent years. There has been a paradigm shift away from blockbusters drugs...Biodexa Pharmaceuticals Enters Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals May 18, 2023
Biodexa Pharmaceuticals recently announced it has signed non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, Inc., a private US precision oncology company developing….
GENE THERAPY - The Role Viral Vectors Play in Current Gene Therapy Development June 4, 2020
Dieter Lingelbach, MBA, discusses the history and science of viral vectors, their current applications, and why they are a vital component in contemporary gene therapy development.
Junshi Biosciences & Merck Announce Collaboration to Explore Promising New Combination Treatment June 2, 2020
Junshi Biosciences and Merck recently announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of…
Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors February 26, 2018
Fate Therapeutics, Inc. recently announced the first subject has been treated in the DIMENSION study of FATE-NK100 for the treatment...ONCOLOGY DIAGNOSTICS - Advancements Paving the Way for More Tailored Drugs November 20, 2017
Divyaa Ravishankar, MS, says pharmaceutical companies have been subjected to a wide variety of external forces compelling them to get innovative about development of new platforms, liaise with new partners, leverage big data toward precision and predictive diagnosis, and identify new markers.
SPECIAL FEATURE - Platform Technologies: Not Just for Big Pharma October 3, 2016
Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.
12/6/2011 December 4, 2011
Nanion's SyncroPatch 96 Convinces Big Pharma Automated Patch Clamp Users Nanion's ion channel screening platform, the SyncroPatch 96, has been...9/6/2011 September 1, 2011
Jennerex's Virus-Based Drug Targets & Infects Tumors Jennerex, Inc. recently announced the publication of clinical data on its lead product...
